Literature DB >> 19826877

Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma.

Seung Hyup Hyun1, Joon Young Choi, Young Mog Shim, Kwhanmien Kim, Su Jin Lee, Young Seok Cho, Ji Young Lee, Kyung-Han Lee, Byung-Tae Kim.   

Abstract

PURPOSE: The aim of this study was to evaluate the prognostic value of metabolic tumor volume (MTV) measured by (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) in patients with esophageal carcinoma.
METHODS: We retrospectively reviewed 151 patients with pathologically proven esophageal carcinoma (146 squamous cell carcinomas and 5 adenocarcinomas) who underwent pretreatment (18)F-FDG PET. MTV and maximum standardized uptake value (SUVmax) for the primary tumors were measured by (18)F-FDG PET. The prognostic significance of MTV, SUVmax, and other clinicopathological variables was assessed by Cox proportional hazards regression analysis. To further evaluate and compare the predictive performance of PET parameters, MTV and SUVmax, time-dependent receiver operating characteristic curve (ROC) analysis was used.
RESULTS: In the univariate analysis, age, American Joint Committee on Cancer (AJCC) stage, tumor-node-metastasis (TNM) factors, MTV, and SUVmax of primary tumor were significant predictors of survival. On multivariate analysis adjusted for age, sex, and treatment modality, independent predictive factors associated with decreased overall survival were T stage [hazard ratio (HR) 4.325, P = 0.006], M stage (HR 2.009, P = 0.007), and MTV (HR 1.013, P = 0.021). SUVmax was not a significant factor (HR 0.97, P = 0.061). On time-dependent ROC analysis, MTV showed good predictive performance for overall survival consistently better than SUVmax.
CONCLUSION: MTV, a volumetric parameter of (18)F-FDG PET, is an important independent prognostic factor for survival and a better predictor of survival than SUVmax for the primary tumor in patients with esophageal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19826877     DOI: 10.1245/s10434-009-0719-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  81 in total

1.  Impact of partial-volume effect correction on the predictive and prognostic value of baseline 18F-FDG PET images in esophageal cancer.

Authors:  Mathieu Hatt; Adrien Le Pogam; Dimitris Visvikis; Olivier Pradier; Catherine Cheze Le Rest
Journal:  J Nucl Med       Date:  2012-01       Impact factor: 10.057

2.  Value of sequential 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in prediction of the overall survival of esophageal cancer patients treated with chemoradiotherapy.

Authors:  Yimin Li; Qin Lin; Zuoming Luo; Long Zhao; Luchao Zhu; Long Sun; Hua Wu
Journal:  Int J Clin Exp Med       Date:  2015-07-15

3.  Prognostic value of metabolic tumor volume and velocity in predicting head-and-neck cancer outcomes.

Authors:  Karen P Chu; James D Murphy; Trang H La; Trevor E Krakow; Andrei Iagaru; Edward E Graves; Annie Hsu; Peter G Maxim; Billy Loo; Daniel T Chang; Quynh-Thu Le
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-01-21       Impact factor: 7.038

4.  Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer.

Authors:  Jong-Ryool Oh; Ji-Hyoung Seo; Ari Chong; Jung-Joon Min; Ho-Chun Song; Young-Chul Kim; Hee-Seung Bom
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-21       Impact factor: 9.236

5.  Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from 18F-FDG PET/CT in operable triple-negative breast cancer.

Authors:  Yong-Il Kim; Yong Joong Kim; Jin Chul Paeng; Gi Jeong Cheon; Dong Soo Lee; June-Key Chung; Keon Wook Kang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-14       Impact factor: 9.236

6.  Change in volume parameters induced by neoadjuvant chemotherapy provide accurate prediction of overall survival after resection in patients with oesophageal cancer.

Authors:  Dietmar Tamandl; Richard M Gore; Barbara Fueger; Patrick Kinsperger; Michael Hejna; Matthias Paireder; Alexander Haug; Sebastian F Schoppmann; Ahmed Ba-Ssalamah
Journal:  Eur Radiol       Date:  2015-06-05       Impact factor: 5.315

7.  PET imaging for prediction of response to therapy and outcome in oesophageal carcinoma.

Authors:  Sue Chua; John Dickson; Ashley M Groves
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09       Impact factor: 9.236

8.  Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.

Authors:  Shengri Liao; Bill C Penney; Kristen Wroblewski; Hao Zhang; Cassie A Simon; Rony Kampalath; Ming-Chi Shih; Naoko Shimada; Sheng Chen; Ravi Salgia; Daniel E Appelbaum; Kenji Suzuki; Chin-Tu Chen; Yonglin Pu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-23       Impact factor: 9.236

Review 9.  State-of-the-art molecular imaging in esophageal cancer management: implications for diagnosis, prognosis, and treatment.

Authors:  Jolinta Lin; Seth Kligerman; Rakhi Goel; Payam Sajedi; Mohan Suntharalingam; Michael D Chuong
Journal:  J Gastrointest Oncol       Date:  2015-02

10.  Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours.

Authors:  Christophe Van de Wiele; Vibeke Kruse; Peter Smeets; Mike Sathekge; Alex Maes
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-14       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.